Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Liabilities and Shareholders Equity (2020 - 2025)

Tango Therapeutics has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $398.7 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $398.7 million for Q4 2025, up 25.97% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 23.04% YoY), and the annual figure for FY2025 was $398.7 million, up 25.97%.
  • Liabilities and Shareholders Equity for Q4 2025 was $398.7 million at Tango Therapeutics, up from $210.1 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for TNGX hit a ceiling of $530.1 million in Q3 2021 and a floor of $167.5 million in Q2 2021.
  • Median Liabilities and Shareholders Equity over the past 5 years was $400.6 million (2023), compared with a mean of $368.9 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 214.84% in 2021 and later crashed 40.37% in 2025.
  • Tango Therapeutics' Liabilities and Shareholders Equity stood at $500.2 million in 2021, then dropped by 12.73% to $436.5 million in 2022, then decreased by 7.77% to $402.6 million in 2023, then dropped by 21.38% to $316.5 million in 2024, then increased by 25.97% to $398.7 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $398.7 million (Q4 2025), $210.1 million (Q3 2025), and $237.9 million (Q2 2025) per Business Quant data.